Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the license agreement and research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the stock purchase agreement between Arrowhead and Johnson & Johnson Innovation – JJDC, Inc., (JJDC) have closed, following termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended.

Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen

Pasadena. CA | Posted on October 31st, 2018

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

or
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie, 212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

A summary of electrospun nanofibers as drug delivery system: This article by Dr. José Manuel Cornejo Bravo et al. is published in Current Drug Delivery, Volume 15 , Issue 10 , 2018 December 14th, 2018

Vitamin E TPGS emulsified vinorelbine bitartrate loaded solid lipid nanoparticles (SLN): This article by Dr. Sanjay Singh et al. is published in Current Drug Delivery, Volume 15 , Issue 8 , 2018 December 14th, 2018

Researchers use jiggly Jell-O to make powerful new hydrogen fuel catalyst: The inexpensive new material can split water just as efficiently as costly platinum December 14th, 2018

IMDEA Nanociencia and Universidad Autónoma de Madrid researchers have demonstrated that graphene deposited on a metal surface promotes an unusual chemical reaction that would hardly take place under noncatalyzed conditions. December 14th, 2018

Investments/IPO's/Splits

180 Degree Capital Corp.’s Portfolio Company, TheStreet, Inc., Agrees to Sell Its Institutional Business Units to Euromoney Institutional Investor PLC for $87.3 Million December 6th, 2018

These small caps are tapping a graphene market that has more than doubled in a year December 1st, 2018

180 Degree Capital Corp. Reports Net Asset Value Per Share of $2.81 as of September 30, 2018; a Decrease of 3.4% From June 30, 2018 October 29th, 2018

180 Degree Capital Corp. to Report Third Quarter 2018 Financial Results on Monday, October 29, 2018 and to Host a Conference Call on Tuesday, October 30, 2018 October 24th, 2018

Nanomedicine

The role of lipid nanoparticles and its surface modification in reaching the brain: This article by Dr. Manoli Igartua et al. is published in Current Drug Delivery, Volume 15, Issue 9, 2018 December 14th, 2018

A summary of electrospun nanofibers as drug delivery system: This article by Dr. José Manuel Cornejo Bravo et al. is published in Current Drug Delivery, Volume 15 , Issue 10 , 2018 December 14th, 2018

Vitamin E TPGS emulsified vinorelbine bitartrate loaded solid lipid nanoparticles (SLN): This article by Dr. Sanjay Singh et al. is published in Current Drug Delivery, Volume 15 , Issue 8 , 2018 December 14th, 2018

Collagen nanofibrils in mammalian tissues get stronger with exercise December 14th, 2018

Announcements

A summary of electrospun nanofibers as drug delivery system: This article by Dr. José Manuel Cornejo Bravo et al. is published in Current Drug Delivery, Volume 15 , Issue 10 , 2018 December 14th, 2018

Vitamin E TPGS emulsified vinorelbine bitartrate loaded solid lipid nanoparticles (SLN): This article by Dr. Sanjay Singh et al. is published in Current Drug Delivery, Volume 15 , Issue 8 , 2018 December 14th, 2018

Researchers use jiggly Jell-O to make powerful new hydrogen fuel catalyst: The inexpensive new material can split water just as efficiently as costly platinum December 14th, 2018

IMDEA Nanociencia and Universidad Autónoma de Madrid researchers have demonstrated that graphene deposited on a metal surface promotes an unusual chemical reaction that would hardly take place under noncatalyzed conditions. December 14th, 2018

Patents/IP/Tech Transfer/Licensing

180 Degree Capital Corp. Announces New Portfolio Holdings – Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen October 4th, 2018

Silvaco, Purdue team up to bring scalable atomistic TCAD solutions for next generation semiconductor devices and materials August 24th, 2018

CTI Materials drives nano commercialization with it's patented surfactant free nanoparticle dispersions August 15th, 2018

Nanobiotechnology

The role of lipid nanoparticles and its surface modification in reaching the brain: This article by Dr. Manoli Igartua et al. is published in Current Drug Delivery, Volume 15, Issue 9, 2018 December 14th, 2018

A summary of electrospun nanofibers as drug delivery system: This article by Dr. José Manuel Cornejo Bravo et al. is published in Current Drug Delivery, Volume 15 , Issue 10 , 2018 December 14th, 2018

Vitamin E TPGS emulsified vinorelbine bitartrate loaded solid lipid nanoparticles (SLN): This article by Dr. Sanjay Singh et al. is published in Current Drug Delivery, Volume 15 , Issue 8 , 2018 December 14th, 2018

Collagen nanofibrils in mammalian tissues get stronger with exercise December 14th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project